AEON Biopharma shares surge 26.15% premarket on positive biosimilarity results and $22M fundraising ahead of FDA meeting.

AEON Biopharma surged 26.15% in premarket trading following two significant announcements. The company secured up to $22 million through a private placement and a convertible note exchange with Daewoong, which will eliminate nearly all outstanding debt and strengthen its balance sheet. Concurrently, AEON reported robust biosimilarity results for ABP-450, confirming 100% amino acid sequence identity with BOTOX® and highly similar functional data, positioning the biosimilar for accelerated FDA approval. These developments, including debt reduction, capital infusion, and critical scientific validation, collectively de-risk the company’s path to market entry in the $3.0 billion U.S. therapeutic neurotoxin sector, driving the sharp premarket increase.